- Report
- January 2026
- 196 Pages
Global
From €3120EUR$3,545USD£2,700GBP
€3467EUR$3,939USD£3,000GBP
- Report
- February 2026
- 250 Pages
Global
From €3952EUR$4,490USD£3,420GBP
- Report
- October 2025
- 160 Pages
Global
From €2955EUR$3,358USD£2,557GBP
€3477EUR$3,950USD£3,008GBP
- Report
- June 2025
- 329 Pages
Global
From €4357EUR$4,950USD£3,770GBP
- Report
- August 2025
- 195 Pages
Global
From €3120EUR$3,545USD£2,700GBP
€3467EUR$3,939USD£3,000GBP
- Report
- January 2026
- 188 Pages
Global
From €3120EUR$3,545USD£2,700GBP
€3467EUR$3,939USD£3,000GBP
- Report
- January 2026
- 192 Pages
Global
From €3120EUR$3,545USD£2,700GBP
€3467EUR$3,939USD£3,000GBP
- Report
- January 2026
- 181 Pages
Global
From €3120EUR$3,545USD£2,700GBP
€3467EUR$3,939USD£3,000GBP
- Report
- June 2025
- 138 Pages
Global
From €3520EUR$3,999USD£3,046GBP
- Report
- February 2026
- 250 Pages
Global
From €3952EUR$4,490USD£3,420GBP
- Report
- February 2026
- 250 Pages
Global
From €3952EUR$4,490USD£3,420GBP
- Report
- August 2025
- 188 Pages
Global
From €3120EUR$3,545USD£2,700GBP
€3467EUR$3,939USD£3,000GBP
- Report
- May 2026
- 273 Pages
Global
From €5149EUR$5,850USD£4,455GBP
- Report
- May 2026
- 196 Pages
Global
From €5149EUR$5,850USD£4,455GBP
- Clinical Trials
- July 2025
- 280 Pages
Global
From €2641EUR$3,000USD£2,285GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2455EUR$2,789USD£2,124GBP
- Report
- June 2025
- 150 Pages
Global
From €2376EUR$2,699USD£2,056GBP
- Report
- June 2025
- 150 Pages
Global
From €2376EUR$2,699USD£2,056GBP
- Report
- August 2025
- 150 Pages
Global
From €4269EUR$4,850USD£3,694GBP
- Report
- September 2024
- 336 Pages
Global
From €4357EUR$4,950USD£3,770GBP

Ranibizumab is a monoclonal antibody used to treat optical disorders such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema secondary to retinal vein occlusion (RVO). It is administered as an intravitreal injection, and works by inhibiting the activity of vascular endothelial growth factor (VEGF), which is responsible for the growth of abnormal blood vessels in the eye. Ranibizumab is the first anti-VEGF drug approved by the US Food and Drug Administration (FDA) for the treatment of wet AMD, and is now widely used in the treatment of other optical disorders.
Ranibizumab is available in both branded and generic forms, and is marketed by a number of pharmaceutical companies, including Novartis, Regeneron, Genentech, and Allergan. Show Less Read more